Ludwig Hantson, Alexion CEO
The lead drug in Alexion’s $930M buyout deal last fall just flopped — adding injury to analysts’ M&A insults
When Alexion $ALXN put down $930 million in cash last fall to buy Achillion, the biotech’s top execs were particularly proud of 2 clinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
